Daniel T.
- Country
- Bulgaria
- Department
- #2223
Research Overview
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
- Phase IV Randomized, Double-Blind, Placebo-Controlled Study of Inclisiran with Lipid-Lowering Therapy in Hypercholesterolemia Patients
- Phase 3 Multicenter Study on Lorundrostat Efficacy and Safety in Uncontrolled and Resistant Hypertension
Data & Insights
Has run more than one trial at 383 of 538 partner sites.
Specializations
Cardiovascular Disease Prevention
The investigator specializes in primary prevention of atherosclerotic cardiovascular disease (ASCVD), focusing on innovative therapeutic approaches for patients at high cardiovascular risk.
- Major Adverse Cardiovascular Events Prevention
- Cardiovascular Risk Management
Their research encompasses comprehensive strategies for preventing cardiac complications, including non-fatal myocardial infarction and ischemic stroke.
Hypertension Management
The investigator conducts extensive research in uncontrolled and resistant hypertension, evaluating novel therapeutic interventions for patients with challenging blood pressure conditions.
- Antihypertensive Treatment Optimization
- Long-term Blood Pressure Control
- Albuminuria Improvement Studies
Their work includes assessment of therapeutic efficacy and safety in both acute and chronic hypertensive conditions.
Lipid Management
The investigator focuses on treating hypercholesterolemia through advanced lipid-lowering therapeutic strategies.
- LDL-Cholesterol Reduction
- Combination Lipid-Lowering Therapy
- Patient Quality of Life Assessment
Their research evaluates the effectiveness of innovative treatments in achieving targeted cholesterol levels while maintaining patient well-being.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.